Brilacidin - Innovation Pharmaceuticals

Drug Profile

Brilacidin - Innovation Pharmaceuticals

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Innovation Pharmaceuticals; HDP-mimic - Innovation Pharmaceuticals; Host defense protein-mimic - Innovation Pharmaceuticals; PMX-30063

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PolyMedix
  • Developer Innovation Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Peptidomimetics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Skin and soft tissue infections; Stomatitis; Ulcerative colitis
  • Preclinical Acne; Atopic dermatitis; Hidradenitis suppurativa
  • No development reported Diabetic foot ulcer; Otitis; Wounds
  • Discontinued Intestinal infections; Ophthalmic infections

Most Recent Events

  • 20 Sep 2018 Innovation Pharmaceuticals plans an end-of-phase II meeting with the FDA in October 2018
  • 05 Sep 2018 Innivation Pharmaceuticals plans a clinical trials for Atopic dermatitis and Acne
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top